Healthcare Industry News: steatohepatitis
News Release - March 15, 2017
Julie G. Anderson Joins BioVie as Independent Director and InvestorBEVERLY, MA--(Healthcare Sales & Marketing Network) - BioVie Inc. (BIVI), a development-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, is pleased to announce the appointment of Julie G. Anderson as an independent member of the Company's Board of Directors. Ms. Anderson brings an impressive experience base in the pharma/biotech industry to BioVie. She also invested personally in the Company.
Ms. Anderson most recently served Catheter Connections, Inc. as its Vice President of Marketing until the company was sold last month. Previously she was Senior Director of Marketing for Durata Therapeutics, Inc., playing a key role in helping build the infrastructure and commercialization plan necessary to launch the novel antibiotic Dalvance. The team's efforts led to an acquisition of the company in 2014 by Actavis (now Allergan) in a deal valued at about $675 million.
Prior to Durata, Julie worked for Sanofi-Synthelabo, Inc., Bayer Pharmaceuticals, and G.D. Searle in various marketing leadership positions. She originally trained as a nurse and earned a Masters of Management at the J.L. Kellogg Graduate School of Management at Northwestern University. As a critical care nurse, Julie treated patients at risk of death due to complications caused by chronic liver cirrhosis, and deeply understands the unmet medical need targeted by BioVie.
"I'm looking forward to working with Julie again," commented CEO Jonathan Adams. "Years ago I worked with her when she led global brand development for Celebrex at Searle. She has tremendous expertise in new drug and market development, underpinned by remarkable skills at devising and executing product commercialization strategies and programs. Combined with her first-hand experience in treating liver cirrhosis patients, she's a perfect fit for helping BioVie advance BIV201 therapy."
BioVie recently submitted a complete response to the U.S. Food and Drug Administration (FDA), addressing the issues identified in the Investigational New Drug Application (IND) clinical hold letter received by the Company in January. If notified by the FDA that clinical development of BIV201 may proceed, BioVie expects to commence a mid-stage (Phase 1b) clinical trial in US ascites patients in the next few months.
About BioVie Inc.
BioVie Inc. is a development-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In late 2016, BioVie submitted an investigational new drug (IND) application to the FDA for BIV201 and is awaiting clearance to begin a clinical trial program. This new drug candidate could potentially enter a mid-stage (Phase 1b) US clinical trial in the first half of 2017. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. It has Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. For more information about BioVie and BIV201, please visit our website: www.biovieinc.com.
About Liver Cirrhosis and Ascites
More than 600,000 Americans and millions worldwide suffer from liver cirrhosis. Cirrhosis is the 12th-leading cause of death due to disease in the US, killing an estimated 40,000 people each year. The condition results primarily from hepatitis, alcoholism, and nonalcoholic steatohepatitis (NASH) linked to fatty liver disease and obesity. Ascites is a common complication of advanced liver cirrhosis. With no medications approved by the FDA specifically for treating ascites, an estimated 40% of patients die within two years of diagnosis. Certain drugs approved for other uses may provide initial relief, but patients often fail to respond to them as ascites worsens. In addition to patient suffering, US treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $4 billion annually.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. BioVie has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are BioVie's need for, and the availability of, substantial capital in the future to fund its operations and research and development; and the risks that BioVie's compounds may experience delays or difficulties in commencing or completing clinical studies, may not successfully complete pre-clinical or clinical testing, or may not be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in BioVie's filings with the Securities and Exchange Commission under its former name. In addition to the risks described above and in BioVie's filings with the SEC, other unknown or unpredictable factors also could affect BioVie's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on any forward-looking statements. BioVie undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation. BioVie cannot assure that the FDA will accept the BIV201 IND filing.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.